Skip to main content
. 2022 Sep 23;14:2885–2902. doi: 10.2147/CMAR.S368381

Figure 1.

Figure 1

EpSSG standard-risk stratification and treatment recommendations for local/locoregional adult-type NRSTS (including synovial sarcoma).

Notes: I-D=ifosfamide (3 g/m² per day intravenously, for 3 days) plus doxorubicin (37.5 mg/m² intravenously per day for 2 days). I=ifosfamide (3 g/m² intravenously per day for 2 days). Ifosfamide should be given with hyperhydration and mesna infusion (3 g/m² per day intravenously). Chemotherapy cycles should be administered every 21 days. *Total of 6 courses for synovial sarcoma, 7 courses for the other adult-type NRSTS.

Abbreviations: IRS, Intergroup Rhabdomyosarcoma Study; IRS group I, complete resection at first surgery (initial R0 surgery); IRS group II, microscopic residual disease after initial R1 surgery); IRS group III, biopsy or initial macroscopic residual disease after R2 surgery; IRS group IV, metastatic disease at onset; G, tumor grade (according to the Fédération Nationale des Centres de Lutte Contre le Cancer grading system); N1, nodal involvement.